The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
WhiteLab Genomics
TechBio company using its ALFRED AI platform to design viral and non-viral delivery vehicles and genetic payloads.
What they do
WhiteLab Genomics closed a $26M Series B in October 2026 led by AVP with Yaday Health, Blast Club, Omnes Capital and Debiopharm Innovation Fund, about $37M raised to date. Its ALFRED platform designs AAV capsids, non-viral vehicles and programmable payloads that are validated in vivo, supporting about 15 partnerships including Sanofi.
The record
- Vertical
- Biotech & Therapeutics
- Sub-segment
- AI-designed genomic medicines
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Paris, France and Boston
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $37M raised
Notable investors: AVP, Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund.
Also in Biotech & Therapeutics
Related on The Signal
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
Do Polygenic Risk Scores Actually Change Clinical Outcomes?
Dr. Dereck Mush, MD, MBA
The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA